But our present data suggest that a treatment based on CSPG4-CAR.CIKs infiltrating cells that will target "CSPG4-high" tumor cells could be interesting if some aspects responsible for the immune desert can be overcome first. This evidence concerns the gene CSPG4 and neoplasm.